Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961028 | 0.88 | GAA (0.63) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL9869942 | 0.86 | GAA (0.69) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL5655786 | 0.85 | KMT2A (0.67) | KMT2AL3MBTL1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL10895253 | 0.82 | GAA (0.71) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL14027684 | 0.79 | TDP1 (0.67) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL6424910 | 0.79 | GAA (0.77) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL29832117 | 0.79 | GAA (0.77) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL9297476 | 0.78 | KMT2A (0.75) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL8110954 | 0.78 | GAA (0.75) | GAAKMT2ACYP2C19KDM4EL3MBTL1 | |
| SCHEMBL14027686 | 0.77 | ALDH1A1 (0.54) | GAALMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | CEREP (FR) | 2005-12-01 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | GAA 1883/4885KMT2A 2124/4885CYP2C19 64/4885 |
| US-20050267126-A1 | Compounds derived from aryl carbamates, preparation thereof and uses of same | HTR4, HTR2B, HTR1B | GAA 2289/4885KMT2A 1571/4885CYP2C19 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.